BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Sanofi  Synthelabo  submitted  on  14  February  2001  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Arixtra, 
through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  30  June  2000,  this  medicinal 
product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 
1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Per Nilsson 
Co-Rapporteur:   Prof Silvio Garattini 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CPMP  on  21-22  October  1997.  The  Scientific 
Advice pertained to part IV of the dossier. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
1.2  Steps taken for the assessment of the product 
• 
The procedure started on 1 March 2001. 
• 
• 
• 
• 
• 
• 
• 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 8 May 2001 
(Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members 
on 10 May 2001 (Annex 2) 
During the meeting on 26-28 June 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
27 June 2001 (Annex 3). 
The company submitted the responses to the CPMP consolidated List of Questions on 9 August 
2001. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s  responses  to  the  List  of  Questions  to  all  CPMP  members  on  27  September  2001 
(Annex 5) 
During  the  CPMP  meeting  on  14  November  2001,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP. 
During  the  meeting  on  11-13  December  2001  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Arixtra on 13 December 2001. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 21 March 2002. 
1/1 
EMEA 2004 
 
 
